Have a personal or library account? Click to login
The levels of bone alkaline phosphatase (BALP) and soluble epidermal growth factor receptor-2 (ECD/HER-2) in pediatric patients with osteosarcoma during clinical treatment Cover

The levels of bone alkaline phosphatase (BALP) and soluble epidermal growth factor receptor-2 (ECD/HER-2) in pediatric patients with osteosarcoma during clinical treatment

Open Access
|Apr 2018

Figures & Tables

Serum levels of BALP and ECD/HER-2 in patients with osteosarcoma during treatment in comparison with healthy age matched counterparts_Tabela I_ Poziomy BALP i ECD/HER-2 w surowicy krwi pacjentów z OS w trakcie leczenia w porównaniu z grupą kontrolną_

Patients (n=22) Pacjenci (n=22) Controls (n=22) Grupa kontrolna (n=22)
Biopsy BiopsjaPre-operative chemotherapy Chemioterapia przedoperacyjnaPost-operative chemotherapy Chemioterapia pooperacyjna
BALP (U/L)136.9 (85.7-240.6)53.8 (40.4-84.8)*63.8 (43.2-82.4)**94.1 (59.4-120.4)**
ECD/HER-2 (ng/ml)4.95 (3.53-12.3)3.86 (2.79-10.08)*3.84 (3.06-20.66)*4.06 (3.29-5.20)*

Serum levels of BALP and ECD/HER-2 in osteosarcoma patients depending on the metastasis status at initial diagnosis_Tabela II_ Stężenie BALP i ECD/HER-2 w surowicy krwi pacjentów z OS_ Pacjenci zostali podzieleni na grupy w zależności od tego czy stwierdzono przerzuty na etapie dinagozy_

Patients with localized disease (n=13) Pacjenci bez przerzutów (n=13)Patients with metastatic disease (n=9) Pacjenci z przerzutami (n=9)
Biopsy BiopsjaPre-operative chemotherapy Chemioterapia przedoperacyjn aPost-operative chemotherapy Chemioterapia pooperacyjnaBiopsy BiopsjaPre-operative chemotherapy Chemioterapia przedoperacyjnaPost-operative chemotherapy Chemioterapia pooperacyjna
BALP (U/L)89.1(75.4-138.8)43.0** (31.9-58.0)50.5** (36.8-80.5)257.0** (216.5-325.7)101.6* (49.7-142.6)71.0* (61.6-114.4)
ECD/HER-2 (ng/ml)4.58 (3.40-14.20)3.86 (2.86-12.9)7.98* (3.31-20.66)5.11(3.68-6.90)3.80 (2.44-5.76)3.62 (2.59-6.88)

Serum levels of BALP and ECD/HER-2 in osteosarcoma patients with remission or progression of disease after therapy_Tabela III_ Poziomy BALP i ECD/HER-2 w surowicy krwi pacjentów z remisją lub progresją choroby po terapii_

Patients with remission (n=16)Pacjenci w remisji (n=16)Patients with progression (n=6)Pacjenci z progresją (n=6)
BALP (U/L)43.6 (38.4-74.6)147.0 (126.5-263.3)*
ECD/HER-2 (ng/ml)3.56 (2.61-37.62)6.41 (4.51-10.59)
DOI: https://doi.org/10.34763/devperiodmed.20182201.5864 | Journal eISSN: 2719-535X | Journal ISSN: 2719-6488
Language: English
Page range: 58 - 64
Submitted on: Nov 29, 2017
|
Accepted on: Dec 6, 2017
|
Published on: Apr 12, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2018 Magdalena Rychłowska-Pruszyńska, Joanna Gajewska, Jadwiga Ambroszkiewicz, Marek Karwacki, Katarzyna Szamotulska, published by Institute of Mother and Child
This work is licensed under the Creative Commons Attribution 4.0 License.